// App-Quantinova.ai

: Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT

Researchers

Presenter

  • Mark Dransfield

Principal Investigators

  • Courtney Crim

  • Gerard Criner

  • David Halpin

  • Meilan Han

  • C. Elaine Jones

  • Sally Kilbride

  • Peter Lange

  • David Lipson

  • David Lomas

  • Fernando Martinez

  • David Singh

  • Robert Wise

Medical Centers

  • Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, United States,

  • GlaxoSmithKline, Research Triangle Park, NC, United States.

  • Lewis Katz School of Medicine at Temple University, Philadelpha , United States of America

  • Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • University of Michigan - Ann Arbor - United States of America

  • GlaxoSmithKline, Stockley Park, United Kingdom

  • University of Copenhagen, Copenhagen E, Denmark

  • GlaxoSmithKline, King of Prussia, United States of America

  • UCL Respiratory, University College London, London, United Kingdom

  • NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, United States of America

  • ARUK Centre for Epidemiology, CfMR, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom

  • Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, United States of America

Locations

  • United States

  • United Kingdom

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved